CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Great Basin Scientific Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Great Basin Scientific Inc
420 East South Temple
Suite 520
Phone: (801) 990-1055p:801 990-1055 Salt Lake City, UT  84111-1362  United States Fax: (801) 990-1051f:801 990-1051
Filed for Bankruptcy on 3/5/2018
Case #18-21367, filed in the U.S. Bankruptcy Court for the District of Utah (Salt Lake City)(Chapter 7)
On 1/20/2017, Great Basin Scientific Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-213144) with the SEC. The Company requests that the Registration Statement be withdrawn because the Company’s management believes that the financing is no longer necessary to fund the ongoing operations of the Company and, in that case, the Company desires, in the best interests of its shareholders, to avoid a potentially unnecessary dilutive financing.
This company is no longer actively traded on any major stock exchange.
Business Summary
Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201712/31/2016YesYesYes-Yes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board DavidSpafford 55
Senior Vice President - Research, Chief Technology Officer RobertJenison 50 1/1/2006 1/1/2006
President, Chief Executive Officer, Director RyanAshton 56 1/1/2005 1/1/2005
3 additional Officers and Directors records available in full report.

Business Names
Business Name
GBSN
GBSND
GBSNQ

General Information
Number of Employees: 70 (As of 6/30/2014)
Outstanding Shares: 5,342,140 (As of 6/20/2017)
Stock Exchange: OTC
Federal Tax Id: 830361454
Fax Number: (801) 990-1051


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023